– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – – Announced Phase 1a interim results for orally bioavailable HDV entry inhibitor candidate ABI-6250 supporting progression into Phase 2 evaluation – – Additional interim Phase 1b data readouts from HSV program anticipated to include monthly oral dosing for ABI-5366 and two cohorts of weekly oral dosing for ABI-1179, with data now expected by end of year – – Raised $175 million gross proceeds from equity financings – SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today...

CHANDLER, Ariz., Nov. 10, 2025 (GLOBE NEWSWIRE) — VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use-of-force and firearms training simulators, reported results for the third quarter ended September 30, 2025. The financial statements are available on VirTra’s website and here. Third Quarter 2025 and Recent Operational HighlightsBookings totaled $8.4 million in Q3 2025. Secured a $4.8 million multi-site contract to deliver law enforcement training systems in Colombia. Validated and approved for full deployment of 20 simulators with the Royal Canadian Mounted Police, expanding VirTra’s installed base and training footprint across Canada. Introduced the V-One Portable Simulator, a compact, high-quality training solution tailored for smaller agencies and mobile training environments. Demonstrated...

Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA meeting OCS-01 DIAMOND Phase 3 trials in diabetic macular edema (DME) remain on track for topline results expected in Q2 2026 Licaminlimab PREDICT-1 registrational trial, the first genotype-based trial to drive precision medicine in dry eye disease (DED), expected to start in Q4 2025 Cash, cash equivalents and short-term investments of $182.2 million as of September 30, 2025 plus recent $110 million financing, extend cash runway into 2029ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations...

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) —Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA meeting OCS-01 DIAMOND Phase 3 trials in diabetic macular edema (DME) remain on track for topline results expected in Q2 2026 Licaminlimab PREDICT-1 registrational trial, the first genotype-based trial to drive precision medicine in dry eye disease (DED), expected to start in Q4 2025 Cash, cash equivalents and short-term investments of $182.2 million as of September 30, 2025 plus recent $110 million financing, extend cash runway into 2029Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations...

Company announcement no. 10 – 25 10 November 2025 NTG Nordic Transport Group publishes interim report for Q3 2025 The interim report for Q3 2025 is enclosed. In connection with publication of the results for Q3 2025, a conference call will be hosted on 11 November 2025 at 10:00 AM CET. The conference call will be held in English and can be followed live via NTG’s website; investor.ntg.com. Additional information For additional information, please contact:Investor relations and press:Sebastian Rosborg,Head of Investor Relations & External Communications +45 42 12 80 99 Sebastian.rosborg@ntg.com ir@ntg.com|press@ntg.com   Attachments NTG Interim Report Q3 2025AttachmentsCompany announcement no. 10_2025NTG Interim Report Q3 2025

PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. HighlightsProgressed clinical development of tecarfarin.Completed the manufacturing of tecarfarin drug product in accordance with current good manufacturing practices (cGMP). Ongoing activities in support of a single-site U.S. Phase 2 study of tecarfarin in LVAD patients as part of the collaboration agreement with Abbott. Investigator discussions for a potential multi-site Phase 2 study of tecarfarin in dialysis patients...

ASHBURN, Va., Nov. 10, 2025 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, has posted its 2025 third quarter financial results on its investor relations website at https://investors.telos.com. Telos will host a live webcast to discuss its third quarter 2025 financial results today, November 10, 2025, at 9:30 a.m. ET. To access the webcast, visit https://edge.media-server.com/mmc/p/fsjkyffa/lan/en. Related presentation materials will be made available on the Investors section of the Company’s website at https://investors.telos.com. In addition, an archived webcast will be available approximately two hours after the conclusion of the live event on the Investors section of the Company’s website.  About Telos...

SINGAPORE, Nov. 10, 2025 (GLOBE NEWSWIRE) — Currenc Group Inc. (Nasdaq: CURR) (“Currenc” or the “Company”), a fintech pioneer empowering financial institutions worldwide with artificial intelligence (AI) solutions, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial HighlightsTotal Processing Value (TPV) through Tranglo was US$1.41 billion for the third quarter of 2025, increasing by 10.1%1 year-over-year. Total number of transactions increased to 3.0 million for the third quarter of 2025 from 2.7 million for the same period of 2024.Total revenues, excluding TNG Asia and GEA2, were US$10.4 million for the third quarter of 2025, representing a year-over-year decrease of 3.9%3, primarily due to lower Indonesian Airtime revenue, partly offset by growth in...

Conference Call Today at 10:00 a.m. Eastern Standard Time Investor Day Scheduled for March 19, 2026, at the new Nashville, TN Campus PARSIPPANY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (Nasdaq: LINC) today announced financial and operating results for the third quarter ended September 30, 2025, as well as recent business developments. Third Quarter Financial and Operational Highlights(Quarter ended September 30, 2025, compared to the quarter ended September 30, 2024, unless otherwise noted) Financial PerformanceRevenue increased $27.0 million, or 23.6% to $141.4 million, or 25.4% excluding the Transitional segment Net income of $3.8 million, or $0.12 per share, compared to $4.0 million, or $0.13 per share last year, when the quarter included a $2.8 million one-time insurance gain Adjusted...

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2025 and provided a corporate update. “With a number of data events expected in the coming months, we remain focused on advancing our programs in chronic urticaria and continue to believe that briquilimab has the potential to serve as a highly differentiated therapeutic in mast cell disease based on the results we’ve generated thus far,” said Ronald Martell, President and Chief Executive Officer of Jasper....